These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9769621)

  • 1. Sublingual morphine: efficacy reviewed.
    Coluzzi PH
    J Pain Symptom Manage; 1998 Sep; 16(3):184-92. PubMed ID: 9769621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
    Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
    Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sublingual and oral morphine administration. Review and new findings.
    Robison JM; Wilkie DJ; Campbell B
    Nurs Clin North Am; 1995 Dec; 30(4):725-43. PubMed ID: 7501539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sublingual morphine may be a suitable alternative for pain control in children in the postoperative period.
    Engelhardt T; Crawford M
    Paediatr Anaesth; 2001 Jan; 11(1):81-3. PubMed ID: 11123737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
    Mercadante S
    Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer.
    Pavis H; Wilcock A; Edgecombe J; Carr D; Manderson C; Church A; Fisher A
    J Pain Symptom Manage; 2002 Dec; 24(6):598-602. PubMed ID: 12551810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic study of sublingual aerosolized morphine in healthy volunteers.
    Watson NW; Taylor KM; Joel SP; Slevin ML; Eden OB
    J Pharm Pharmacol; 1996 Dec; 48(12):1256-9. PubMed ID: 9004187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublingual methadone for the management of cancer-related breakthrough pain: a pilot study.
    Hagen NA; Fisher K; Stiles C
    J Palliat Med; 2007 Apr; 10(2):331-7. PubMed ID: 17472503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.
    Portenoy RK; Payne R; Coluzzi P; Raschko JW; Lyss A; Busch MA; Frigerio V; Ingham J; Loseth DB; Nordbrock E; Rhiner M
    Pain; 1999 Feb; 79(2-3):303-12. PubMed ID: 10068176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingual Versus Swallowed Morphine: A Comparison.
    Dyal BW; Powell-Roach KL; Robison J; Campbell B; Yoon SL; Wilkie DJ
    Cancer Nurs; 2021; 44(1):E13-E22. PubMed ID: 31895174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual absorption of selected opioid analgesics.
    Weinberg DS; Inturrisi CE; Reidenberg B; Moulin DE; Nip TJ; Wallenstein S; Houde RW; Foley KM
    Clin Pharmacol Ther; 1988 Sep; 44(3):335-42. PubMed ID: 2458208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone.
    Collins JJ; Geake J; Grier HE; Houck CS; Thaler HT; Weinstein HJ; Twum-Danso NY; Berde CB
    J Pediatr; 1996 Nov; 129(5):722-8. PubMed ID: 8917240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
    Jandhyala R; Fullarton JR; Bennett MI
    J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of regularly administered sustained release oral morphine with intramuscular morphine for control of postoperative pain.
    Bourke M; Hayes A; Doyle M; McCarroll M
    Anesth Analg; 2000 Feb; 90(2):427-30. PubMed ID: 10648333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).
    Coluzzi PH; Schwartzberg L; Conroy JD; Charapata S; Gay M; Busch MA; Chavez J; Ashley J; Lebo D; McCracken M; Portenoy RK
    Pain; 2001 Mar; 91(1-2):123-30. PubMed ID: 11240084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids.
    Mercadante S; Adile C; Cuomo A; Aielli F; Marinangeli F; Casuccio A
    Support Care Cancer; 2017 Feb; 25(2):645-649. PubMed ID: 27744534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids for the management of breakthrough (episodic) pain in cancer patients.
    Zeppetella G; Ribeiro MD
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004311. PubMed ID: 16437482
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.